IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC boosted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 108,649 shares of the company’s stock after purchasing an additional 3,749 shares during the period. Stephens Investment Management Group LLC’s holdings in IDEXX Laboratories were worth $44,920,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Livforsakringsbolaget Skandia Omsesidigt lifted its stake in shares of IDEXX Laboratories by 400.0% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 500 shares of the company’s stock worth $253,000 after acquiring an additional 400 shares in the last quarter. Perfromance Wealth Partners LLC raised its position in shares of IDEXX Laboratories by 3.2% in the 3rd quarter. Perfromance Wealth Partners LLC now owns 3,526 shares of the company’s stock valued at $1,781,000 after purchasing an additional 110 shares in the last quarter. Gateway Investment Advisers LLC boosted its stake in shares of IDEXX Laboratories by 1.2% during the 3rd quarter. Gateway Investment Advisers LLC now owns 11,075 shares of the company’s stock valued at $5,595,000 after buying an additional 134 shares during the last quarter. Carnegie Investment Counsel acquired a new stake in shares of IDEXX Laboratories during the third quarter worth approximately $205,000. Finally, CHICAGO TRUST Co NA increased its stake in shares of IDEXX Laboratories by 29.3% in the third quarter. CHICAGO TRUST Co NA now owns 3,990 shares of the company’s stock worth $2,016,000 after buying an additional 904 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Barclays increased their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Bank of America boosted their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Leerink Partners began coverage on IDEXX Laboratories in a report on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price on the stock. Piper Sandler reiterated a “neutral” rating and issued a $435.00 price target (down from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Finally, StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $524.38.

IDEXX Laboratories Stock Performance

IDXX stock opened at $459.78 on Friday. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The stock has a market capitalization of $37.65 billion, a price-to-earnings ratio of 43.09, a PEG ratio of 3.47 and a beta of 1.37. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.03 and a current ratio of 1.31. The stock’s fifty day moving average is $428.35 and its two-hundred day moving average is $453.56.

Insider Activity at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the sale, the director now directly owns 905 shares in the company, valued at $380,498.20. This trade represents a 27.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.11% of the stock is currently owned by insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.